L'IRM est-elle utile dans le suivi des patients atteints de sclérose en plaques ? Non / Is MRI monitoring useful in clinical practice in patients with multiple sclerosis? No.

Gilles Edan 1, 2, 3, *
* Corresponding author
1 VisAGeS - Vision, Action et Gestion d'informations en Santé
INSERM - Institut National de la Santé et de la Recherche Médicale : U746, Inria Rennes – Bretagne Atlantique , IRISA-D5 - SIGNAUX ET IMAGES NUMÉRIQUES, ROBOTIQUE
Abstract : Is regular MRI monitoring useful in clinical practice in multiple sclerosis patients treated with disease modifying therapy (DMT) drugs? My answer is no. Tacking a DMT drug is not by itself a pertinent criterion for requiring a systematic MRI monitoring in MS patients. Five clinical criteria should be taken into consideration before prescribing regular MRI examinations. The clinical form of the disease: MRI monitoring in DMT treated patients, has been demonstrated as useful only in pure relapsing-remitting MS patients. Up to now, there is no convincing demonstration of therapeutic efficacy with any DMT drug, neither first-line nor second-line drugs in patients with primary or secondary progressive MS disease. The duration of the disease, epidemiological data leading to the concept of a two-stage disability progression in MS, emphasizes the importance of treating as early as possible RRMS patients in order to stop accumulation of new focal MRI CNS lesions. In this regard, an annual monitoring for the 5 first years of the disease looks reasonable in order to better personalize the treatment choice among the few approved DMT drugs. The duration of the treatment: a first MRI assessment at month 6 after initiating a new DMT drug is adequate in order to better distinguish responder versus no responder. The persistence of Gado+lesions at 6 months is a strong indication for considering alternative treatment. The disease activity: both criteria, clinical and MRI, are needed to recognized very active or aggressive relapsing MS patients, leading to decide a rapid use of second-line treatment therapy. The treatment choice: in JC positive MS patients treated with natalizumab, the risk of PML is as high as more than 1 % in those JC+MS patients that are treated continuously more than 24 months. A regular MRI monitoring (3 or 6months) is recommended in order to detect as early as possible MRI abnormalities suggesting PML.
Document type :
Journal articles
Complete list of metadatas

https://hal-univ-rennes1.archives-ouvertes.fr/hal-00931687
Contributor : Marie Lecoupe-Grainville <>
Submitted on : Wednesday, January 15, 2014 - 3:58:24 PM
Last modification on : Monday, March 4, 2019 - 2:08:20 PM

Identifiers

Citation

Gilles Edan. L'IRM est-elle utile dans le suivi des patients atteints de sclérose en plaques ? Non / Is MRI monitoring useful in clinical practice in patients with multiple sclerosis? No.. Revue Neurologique, Elsevier Masson, 2013, 169 (11), pp.864-8. ⟨10.1016/j.neurol.2013.08.004⟩. ⟨hal-00931687⟩

Share

Metrics

Record views

325